创伤严重程度与肝素诱导性血小板减少症抗体血清转换的关联:一项多中心、前瞻性、观察性研究
该多中心前瞻性观察研究纳入2018年3月至2019年2月年龄≥18岁、ISS≥9的创伤患者184例,按创伤严重程度分为轻度(ISS 9-15,55例)、中度(ISS 16-24,62例)和重度(ISS≥25,67例)三组,比较抗体血清转换时间、转换率及第30天抗体消失率。总体抗PF4/肝素IgG和HIT抗体(洗涤血小板活化试验)血清转换率分别为26.6%和16.3%,两组抗体血清转换率在三组间均有显著差异(P=0.016和P=0.046),且随创伤严重程度增加而升高。血清转换时间无论是否使用肝素均在伤后5至10天;第30天时,28.6%的抗PF4/肝素IgG和60.9%的HIT抗体血清转换患者抗体不再检测到。作者认为HIT抗体在严重创伤患者中常见,其产生可能与创伤严重程度相关。
要点
- 严重创伤患者(ISS≥25)抗PF4/肝素IgG和HIT抗体血清转换率随创伤严重程度增加而升高,三组间差异显著(P=0.016和P=0.046)。
- 总体抗PF4/肝素IgG血清转换率为26.6%,HIT抗体(洗涤血小板活化试验)血清转换率为16.3%。
- 无论是否使用肝素,血清转换时间均在伤后5至10天。
- 第30天时,28.6%的抗PF4/肝素IgG血清转换者和60.9%的HIT抗体血清转换者抗体不再检测到。
- HIT抗体在严重创伤患者中常见,其产生可能与创伤严重程度相关。
适用人群与场景
- 2018年3月至2019年2月纳入的年龄18岁或以上、损伤严重度评分(ISS)≥9的创伤患者。
- 包括未接受任何肝素的患者,以及仅接受肝素冲管或接受肝素治疗的患者。
诊断标准与关键阈值
- 按创伤严重程度分组:轻度损伤组ISS 9-15,中度损伤组ISS 16-24,重度损伤组ISS≥25。
- 抗PF4/肝素IgG血清转换和HIT抗体血清转换分别采用相应检测方法(HIT抗体采用洗涤血小板活化试验)判定。
研究设计与关键结果
- 多中心、前瞻性、观察性研究,共纳入184例创伤患者,轻度损伤组55例、中度损伤组62例、重度损伤组67例。
- 总体抗PF4/肝素IgG血清转换率为26.6%,HIT抗体(洗涤血小板活化试验)血清转换率为16.3%。
- 三组间抗PF4/肝素IgG血清转换率差异显著(P=0.016),HIT抗体血清转换率差异显著(P=0.046)。
- 两种检测的血清转换率均随创伤严重程度增加而升高。
- 无论是否使用肝素,达到血清转换所需时间相似,均在伤后5至10天。
- 第30天时,28.6%的抗PF4/肝素IgG血清转换患者和60.9%的HIT抗体血清转换患者抗体不再检测到。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、观察性研究。
- 证据等级:治疗/护理管理;Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,HIT抗体在严重创伤患者中常见,HIT抗体产生可能与创伤严重程度相关,且第30天抗体消失频率较高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Heparin administration can induce the production of anti-platelet factor 4 (PF4)/heparin antibodies with platelet-activating properties, causing heparin-induced thrombocytopenia (HIT). Previous studies have suggested that trauma severity influences HIT immune responses, but their relationship has not been fully explained. This study aimed to clarify this association by multicenter prospective observational study.
METHODS: Trauma patients who met the criteria of age 18 years or older and Injury Severity Scores (ISSs) of ≥9 from March 2018 to February 2019 were included. Patients who did not receive any heparin and those who received it as flushes or for treatment were also included. Patients were divided into three groups based on trauma severity (to mild [ISS 9-15], moderate [ISS 16-24], and severe injury groups [ISS ≥25]) and were compared by the seroconversion time and rate, as well as the disappearance rate of antibodies on day 30.
RESULTS: A total of 184 patients were included: 55, 62, and 67 patients were classified into the mild, moderate, and severe injury groups, respectively. Overall, the seroconversion rates of anti-PF4/heparin immunoglobulin G (IgG) and HIT antibodies by washed platelet activation assay were 26.6% and 16.3%, respectively. There was a significant difference in the seroconversion rates of anti-PF4/heparin IgG ( p = 0.016) and HIT antibodies ( p = 0.046) among the groups. Seroconversion rates in both assays increased with increasing trauma severity. The time required to achieve seroconversion was similar (between 5 and 10 days of trauma onset) regardless of heparin administration. Anti-PF4/heparin IgG and HIT antibodies were no longer detected on day 30 in 28.6% and 60.9% of seroconverted patients, respectively.
CONCLUSION: Development of HIT antibodies was observed commonly in severely injured trauma patients. Heparin-induced thrombocytopenia antibody development may be related to trauma severity, with a high disappearance frequency on day 30.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Fujita M, Maeda T, Miyata S, et al. Association of trauma severity with antibody seroconversion in heparin-induced thrombocytopenia: A multicenter, prospective, observational study. J Trauma Acute Care Surg. 2022. PMID: 35271548. doi:10.1097/TA.0000000000003603
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。